Clinical trial · Interventional
Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer
Phase III Randomized Study of Surgical Resection With Versus Without Postoperative Hepatic Arterial Chemotherapy in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving drugs directly into the arteries around the tumor may kill more tumor cells. Giving chemotherapy after surgery may kill any remaining tumor cells. It is not yet known whether surgery and hepatic arterial chemotherapy are more effective than surgery alone in treating patients with liver cancer that has spread to the portal vein. PURPOSE: This randomized phase III trial is studying surgery and hepatic arterial chemotherapy to see how well they work compared to surgery alone in treating patients with liver cancer that has spread to the portal vein.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Localized Resectable Adult Primary Liver Cancer | — | UNRESOLVED | — |
| Stage III Childhood Liver Cancer | Childhood Malignant Liver Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adjuvant therapy | Procedure | — | UNRESOLVED |
| chemotherapy | Procedure | — | UNRESOLVED |
| cisplatin | Drug | Cisplatin | ALIAS |
| conventional surgery | Procedure | — | UNRESOLVED |
| fluorouracil | Drug | Fluorouracil | ALIAS |
| hepatic arterial infusion | Procedure | — | UNRESOLVED |
| surgery | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed hepatocellular carcinoma (HCC) with portal vein tumor thrombus * Tumor thrombus in the main trunk or first branch of the portal vein * No apparent distant metastases on chest CT scan and bone scintigraphy within the past 6 weeks * No pleural effusion or ascites PATIENT CHARACTERISTICS: Age * Not specified Performance status * ECOG 0-1 Life expectancy * Not specified Hematopoietic * Neutrophil count \> 1,000/mm\^3 * Platelet count \> 50,000/mm\^3 * Hemoglobin \> 8 g/dL Hepatic * Bilirubin \< 2 times upper limit of normal (ULN) * ALT and AST \< 4 times ULN Renal * Creatinine normal Cardiovascular * No severe heart disease * No cardiac effusion Other * No other malignant disease * No high risk for esophageal varices rupture * No allergy to fluorouracil or cisplatin PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * No prior hepatic arterial chemotherapy * No prior systemic chemotherapy for HCC Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified
References
Publications (0)
Data not yet available